Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 4/2008

01-04-2008 | Special Position Paper

Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA

Authors: B. Dawson-Hughes, A. N. A. Tosteson, L. J. Melton III, S. Baim, M. J. Favus, S. Khosla, R. L. Lindsay

Published in: Osteoporosis International | Issue 4/2008

Login to get access

Abstract

Summary

Application of the WHO fracture prediction algorithm in conjunction with an updated US economic analysis indicates that osteoporosis treatment is cost-effective in patients with fragility fractures or osteoporosis, in older individuals at average risk and in younger persons with additional clinical risk factors for fracture, supporting existing practice recommendations.

Introduction

The new WHO fracture prediction algorithm was combined with an updated economic analysis to evaluate existing NOF guidance for osteoporosis prevention and treatment.

Methods

The WHO fracture prediction algorithm was calibrated to the US population using national age-, sex- and race-specific death rates and age- and sex-specific hip fracture incidence rates from the largely white population of Olmsted County, MN. Fracture incidence for other races was estimated by ratios to white women and men. The WHO algorithm estimated the probability (%) of a hip fracture (or a major osteoporotic fracture) over 10 years, given specific age, gender, race and clinical profiles. The updated economic model suggested that osteoporosis treatment was cost-effective when the 10-year probability of hip fracture reached 3%.

Results

It is cost-effective to treat patients with a fragility fracture and those with osteoporosis by WHO criteria, as well as older individuals at average risk and osteopenic patients with additional risk factors. However, the estimated 10-year fracture probability was lower in men and nonwhite women compared to postmenopausal white women.

Conclusions

This analysis generally endorsed existing clinical practice recommendations, but specific treatment decisions must be individualized. An estimate of the patient’s 10-year fracture risk should facilitate shared decision-making.
Literature
1.
2.
Kanis JA, Melton LJ III, Christiansen C et al (1994) The diagnosis of osteoporosis. J Bone Miner Res 9:1137–1141PubMedCrossRef
3.
Kanis JA, Johnell O, De Laet C et al (2004) A meta-analysis of previous fracture and subsequent fracture risk. Bone 35:375–382PubMedCrossRef
4.
U. S. Preventive Services Task Force (2002) Screening for osteoporosis in postmenopausal women: recommendations and rationale. Ann Intern Med 137:526–528
5.
Eddy D, Johnston CC, Cummings SR et al (1998) Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Osteoporos Int 8 Suppl 4:S7–80
6.
Rossouw JE, Anderson GL, Prentice RL et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333PubMedCrossRef
7.
Anderson GL, Limacher M, Assaf AR et al (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial.[see comment]. JAMA 291:1701–1712PubMedCrossRef
8.
9.
U.S.D.H.H.S. (2004) Chapter 4. The Frequency of Bone Disease. Bone Health and Osteoporosis: A Report of the Surgeon General. U.S. Department of Health and Human Services, Rockville, MD, pp 69–87
10.
Burge R, Dawson-Hughes B, Solomon DH et al (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res 22:465–475PubMedCrossRef
11.
Börgstrom F, Johnell O, Kanis JA et al (2006) At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis. Osteoporos Int 17:1459–1471PubMedCrossRef
12.
13.
14.
Murphy DJ, Gahm GJ, Santilli S et al (2002) Seniors’ preferences for cancer screening and medication use based on absolute risk reduction. J Gerontol A Biol Sci Med Sci 57A:M100–105
15.
Leslie WD, Siminoski K, Brown JP (2007) Comparative effects of densitometric and absolute fracture risk classification systems on projected intervention rates in postmenopausal women. J Clin Densitom 10:124–131PubMedCrossRef
16.
Bonjour P, Clark P, Cooper C et al. (2007) Assessment of Osteoporosis at the Primary Care Level. WHO Technical Report Series. WHO, Geneva
17.
Oden A, Dawson A, Dere W et al (1998) Lifetime risk of hip fracture is underestimated. Osteoporos Int 8:599–603PubMedCrossRef
18.
Looker AC, Wahner HW, Dunn WL et al (1998) Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 8:468–489PubMedCrossRef
19.
Kanis JA, Oden A, Johnell O et al (2007) The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18:1033–1046PubMedCrossRef
20.
Arias E, Anderson RN, Kung HC et al (2003) Deaths: final data for 2001. Natl Vital Stat Rep 52:1–115PubMed
21.
Melton LJ III, Crowson CS, O’Fallon WM (1999) Fracture incidence in Olmsted County, Minnesota: Comparison of urban with rural rates and changes in urban rates over time. Osteoporos Int 9:29–37PubMedCrossRef
22.
Arneson TJ, Melton LJ III, Lewallen DG et al (1988) Epidemiology of diaphyseal and distal femoral fractures in Rochester, Minnesota, 1965–1984. Clin Orthop 234:188–194PubMed
23.
Bauer RL (1988) Ethnic differences in hip fracture: a reduced incidence in Mexican Americans. Am J Epidemiol 127:145–149PubMed
24.
Silverman SL, Madison RE (1988) Decreased incidence of hip fracture in Hispanics, Asians, and blacks: California Hospital Discharge Data. Am J Public Health 78:1482–1483PubMed
25.
Jacobsen SJ, Goldberg J, Miles TP et al (1990) Hip fracture incidence among the old and very old: a population-based study of 745,435 cases. Am J Public Health 80:871–873PubMed
26.
Griffin MR, Ray WA, Fought RL et al (1992) Black-white differences in fracture rates. Am J Epidemiol 136:1378–1385PubMed
27.
Baron JA, Barrett J, Malenka D et al (1994) Racial differences in fracture risk. Epidemiology 5:42–47PubMedCrossRef
28.
Baron JA, Karagas M, Barrett J et al (1996) Basic epidemiology of fractures of the upper and lower limb among Americans over 65 years of age. Epidemiology 7:612–618PubMedCrossRef
29.
Zingmond DS, Melton LJ 3rd, Silverman SL (2004) Increasing hip fracture incidence in California Hispanics, 1983 to 2000. Osteoporos Int 15:603–610PubMedCrossRef
30.
Lauderdale DS, Jacobsen SJ, Furner SE et al (1998) Hip fracture incidence among elderly Hispanics. Am J Public Health 88:1245–1247PubMedCrossRef
31.
Lauderdale DS, Jacobsen SJ, Furner SE et al (1997) Hip fracture incidence among elderly Asian-American populations. Am J Epidemiol 146:502–509PubMed
32.
Cummings SR, Melton LJ (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359:1761–1767PubMedCrossRef
33.
Kanis JA, Borgstrom F, De Laet C et al (2005) Assessment of fracture risk. Osteoporos Int 16:581–589PubMedCrossRef
34.
Flegal KM, Carroll MD, Ogden CL et al (2002) Prevalence and trends in obesity among US adults, 1999–2000. JAMA 288:1723–1728PubMedCrossRef
35.
Ogden CL, Fryar CD, Carroll MD et al (2004) Mean body weight, height, and body mass index, United States 1960–2002. Adv Data 347:1–17PubMed
36.
Kanis JA, Black D, Cooper C et al (2002) A new approach to the development of assessment guidelines for osteoporosis. Osteoporos Int 13:527–536PubMedCrossRef
37.
Delmas PD, Rizzoli R, Cooper C et al (2005) Treatment of patients with postmenopausal osteoporosis is worthwhile. The position of the International Osteoporosis Foundation. Osteoporos Int 16:1–5PubMedCrossRef
38.
Lewiecki EM (2005) Review of guidelines for bone mineral density testing and treatment of osteoporosis. Curr Osteoporos Rep 3:75–83PubMedCrossRef
39.
Kanis JA, Borgstrom F, Zethraeus N et al (2005) Intervention thresholds for osteoporosis in the UK. Bone 36:22–32PubMedCrossRef
40.
Kanis JA, Johnell O, Oden A et al (2005) Intervention thresholds for osteoporosis in men and women: a study based on data from Sweden. Osteoporos Int 16:6–14PubMedCrossRef
41.
42.
43.
Siris ES, Chen YT, Abbott TA et al (2004) Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 164:1108–1112PubMedCrossRef
44.
Pasco JA, Seeman E, Henry MJ et al (2006) The population burden of fractures originates in women with osteopenia, not osteoporosis. Osteoporos Int 17:1404–1409PubMedCrossRef
45.
Sanders KM, Nicholson GC, Watts JJ et al (2006) Half the burden of fragility fractures in the community occur in women without osteoporosis. When is fracture prevention cost-effective? Bone 38:694–700PubMedCrossRef
46.
Cummings SR, Black DM, Thompson DE et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280:2077–2082PubMedCrossRef
47.
De Laet C, Oden A, Johansson H et al (2005) The impact of the use of multiple risk indicators for fracture on case-finding strategies: a mathematical approach. Osteoporos Int 16:313–318PubMedCrossRef
48.
Schousboe JT, Ensrud KE, Nyman JA et al (2005) Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women. J Am Geriatr Soc 53:1697–1704PubMedCrossRef
49.
Kanis JA, Johansson H, Oden A et al (2004) A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 19:893–899PubMedCrossRef
50.
Anonymous (2001) Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Arthritis Rheum 44:1496–1503CrossRef
51.
U.S.D.H.H.S. (2004) Chapter 3. Diseases of Bone. In Bone Health and Osteoporosis: A Report of the Surgeon General. U.S. Department of Health and Human Services, Office of the Surgeon General, Rockville, MD, pp 41–65
52.
Alam NM, Archer JA, Lee E (2004) Osteoporotic fragility fractures in African Americans: under-recognized and undertreated. J Natl Med Assoc 96:1640–1645PubMed
53.
Farley JF, Cline RR, Gupta K (2006) Racial variations in antiresorptive medication use: results from the 2000 Medical Expenditure Panel Survey (MEPS). Osteoporos Int 17:395–404PubMedCrossRef
54.
Melton LJ III, Marquez MA, Achenbach SJ et al (2002) Variations in bone density among persons of African heritage. Osteoporos Int 13:551–559CrossRef
55.
Barrett-Connor E, Siris ES, Wehren LE et al (2005) Osteoporosis and fracture risk in women of different ethnic groups. J Bone Miner Res 20:185–194PubMedCrossRef
56.
Cauley JA, Lui LY, Ensrud KE et al (2005) Bone mineral density and the risk of incident nonspinal fractures in black and white women. JAMA 293:2102–2108PubMedCrossRef
57.
Hanlon JT, Landerman LR, Fillenbaum GG et al (2002) Falls in African American and white community-dwelling elderly residents. J Gerontol: Med Sci 57A:M473–478
58.
Melton LJ III, Cooper C (2001) Magnitude and impact of osteoporosis and fractures. In: Marcus R, Feldman D, Kelsey J (eds) Osteoporosis. Academic Press, San Diego, pp 557–567CrossRef
59.
Stafford RS, Drieling RL, Hersh AL (2004) National trends in osteoporosis visits and osteoporosis treatment, 1988–2003. Arch Intern Med 164:1525–1530PubMedCrossRef
60.
61.
Schousboe JT, Nyman JA, Kane RL et al (2005) Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women. Ann Intern Med 142:734–741PubMed
62.
Elliot-Gibson V, Bogoch ER, Jamal SA et al (2004) Practice patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: a systematic review. Osteoporos Int 15:767–778PubMed
63.
Browner WS (2007) Predicting fracture risk: tougher than it looks. BoneKEy 4:226–230
64.
Ettinger B, Hillier TA, Pressman A et al (2005) Simple computer model for calculating and reporting 5-year osteoporotic fracture risk in postmenopausal women. J Women’s Health 14:159–171CrossRef
Metadata
Title
Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA
Authors
B. Dawson-Hughes
A. N. A. Tosteson
L. J. Melton III
S. Baim
M. J. Favus
S. Khosla
R. L. Lindsay
Publication date
01-04-2008
Publisher
Springer-Verlag
Published in
Osteoporosis International / Issue 4/2008
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-008-0559-5

Other articles of this Issue 4/2008

Osteoporosis International 4/2008 Go to the issue

Original Article

Loss of treatment benefit due to low compliance with bisphosphonate therapy

Editorial

Assessment of 10-year absolute fracture risk: a new paradigm with worldwide application

Letter to the Editor

Expressing fracture risk

Original Article

Estrogen receptor α CA dinucleotide repeat polymorphism is associated with rate of bone loss in perimenopausal women and bone mineral density and risk of osteoporotic fractures in postmenopausal women

Original Article

The osteoporosis care gap in men with fragility fractures: the Canadian Multicentre Osteoporosis Study

Special Position Paper

Cost-effective osteoporosis treatment thresholds: the United States perspective